Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality affordable medicines and products.

Aspen has a market capitalisation of approximately US$10 billion, is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks among the top 20 listed companies on this exchange.

As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential.

Aspen has a strong global presence in both emerging and developed countries with more than 60 established business operations in approximately 50 countries.  The Group has 26 manufacturing facilities at 18 sites across 6 continents and has more than 10 000 employees.

Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.


Latest News

Aspen’s response to Guardian article : 28 January 2017

Durban – It is important to respond to the issues raised pertaining to Aspen in the article published in the Guardian …

Read more »

Stephen Saad scoops Entrepreneur of the Year Award

Johannesburg. Stephen Saad, Aspen Group Chief Executive, was announced as the winner of the Entrepreneur of the Year Award at the …

Read more »

Aspen’s comparable revenue increases by 12% to R35.4 billion

Aspen’s comparable revenue increases by 12% to R35.4 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical …

Read more »

More News

Featured Video

Aspen’s half year gross revenue surged by 47% to R19 billion. CNBC Africa’s David Williams chatted with Aspen Group Chief Executive Stephen Saad about the results.

More Videos

Investor Information

Aspen 2016 Results:

Aspen 2016 Integrated Report

Download PDF

Aspen 2016 Annual Financial Statements

Download PDF

Aspen 2016 Corporate Brochure

Download PDF

Aspen 2016 Year End Results Presentation

Download PDF

Aspen 2016 Year End Results Short Form Announcement

Download PDF

Aspen 2016 Year End Results Commentary (SENS)

Download PDF

Aspen 2016 Fact Sheet

Download PDF